Peter Thiel is the newest non-executive level board member of AbCellera Biologics Inc., a Canadian-based platform for antibody drug discovery. In the next week, the company is expected to make the announcement of their intention to list on Nasdaq at a valuation of several billion dollars. Thiel's experience of scaling technology can prove valuable as the company completes development of a monoclonal antibody treatment for COVID-19 mild to moderate symptoms.
Comments